Teva Pharma (TEVA) Gets Favorable Outcome in Copaxone Suit (MNTA) (MYL)
Tweet Send to a FriendGet Alerts TEVA Hot Sheet
Price: $39.34 -0.38%
Overall Analyst Rating:
NEUTRAL (
Up)
Dividend Yield: 3.2%
Revenue Growth %: -3.9%
Overall Analyst Rating:
NEUTRAL (
Up)Dividend Yield: 3.2%
Revenue Growth %: -3.9%
Trade TEVA Now!
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announced today the U.S. District Court for the Southern District of New York has found in favor of Teva in the Company’s patent infringement lawsuit against Momenta Pharmaceuticals, Inc./Sandoz Inc. (Nasdaq: MNTA) and Mylan Laboratories Inc. (Nasdaq: MYL)/Natco Pharmaceuticals regarding Teva’s relapsing-remitting multiple sclerosis (RRMS) product, COPAXONE. Teva filed suit against Momenta/Sandoz and Mylan/Natco for infringement of multiple patents covering the chemical composition of COPAXONE, methods of using the product and processes for manufacturing the product. This decision covers several patents, the last of which expires on September 1, 2015.
The judge rejected Momenta/Sandoz and Mylan/Natco’s claims that the COPAXONE® patents are invalid and unenforceable and found that the purported generic versions of COPAXONE® for which Momenta/Sandoz and Mylan/Natco seek Food and Drug Administration (FDA) approval infringe those patents. This ruling should prevent the FDA from approving, and the defendants from selling their purported generic versions of COPAXONE® in the U.S. until the Orange Book patents expire on May 24, 2014. As a result of this ruling, Teva also believes that the defendants will be enjoined from selling their products until the process patent expires on September 1, 2015. Furthermore, any purported generic version of COPAXONE® would need to obtain FDA approval prior to being made available to the public. At this point, it is unclear what the requirements would be for approval of a purported generic synthetic peptide.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
The judge rejected Momenta/Sandoz and Mylan/Natco’s claims that the COPAXONE® patents are invalid and unenforceable and found that the purported generic versions of COPAXONE® for which Momenta/Sandoz and Mylan/Natco seek Food and Drug Administration (FDA) approval infringe those patents. This ruling should prevent the FDA from approving, and the defendants from selling their purported generic versions of COPAXONE® in the U.S. until the Orange Book patents expire on May 24, 2014. As a result of this ruling, Teva also believes that the defendants will be enjoined from selling their products until the process patent expires on September 1, 2015. Furthermore, any purported generic version of COPAXONE® would need to obtain FDA approval prior to being made available to the public. At this point, it is unclear what the requirements would be for approval of a purported generic synthetic peptide.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Merck (MRK) Says Efficacy Not Achieved in Preladenant Phase 3s; Will Discontinue
- Biogen Idec (BIIB) Appoints Spyros Artavanis-Tsakonas as CSO
- A.G. Lafley Returns as President/CEO of Procter & Gamble (PG)
Create E-mail Alert Related Categories
Corporate News, FDA
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
